{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:41:55Z","timestamp":1793331715296,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clinre.2025.102699","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T07:29:14Z","timestamp":1759303754000},"page":"102699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness and safety of third-line advanced therapies in patients with ulcerative colitis: A multicentre retrospective cohort study"],"prefix":"10.1016","volume":"49","author":[{"given":"Ana\u00efs","family":"Bertrand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Kirchgesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Uzzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vered","family":"Abitbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Gagni\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Seksik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6676-1222","authenticated-orcid":false,"given":"Aurelien","family":"Amiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2025.102699_bib0001","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.clinre.2025.102699_bib0002","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2025.102699_bib0003","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2025.102699_bib0004","article-title":"Management of non-response and loss of response to anti-tumor necrosis factor therapy in inflammatory bowel disease","volume":"9","author":"Marsal","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clinre.2025.102699_bib0005","doi-asserted-by":"crossref","DOI":"10.1002\/ueg2.12492","article-title":"Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: a multicenter international study","author":"Allocca","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.clinre.2025.102699_bib0006","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/apt.16463","article-title":"Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: a GETAID cohort","volume":"54","author":"Uzzan","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinre.2025.102699_bib0007","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/apt.15717","article-title":"Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study","volume":"51","author":"Amiot","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinre.2025.102699_bib0008","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/apt.16544","article-title":"Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study","volume":"54","author":"Fumery","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinre.2025.102699_bib0009","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cgh.2019.07.005","article-title":"Ulcerative colitis and Crohn\u2019s disease have similar burden and goals for treatment","volume":"18","author":"Le Berre","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2025.102699_bib0010","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cgh.2016.08.044","article-title":"Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists","volume":"15","author":"Feagan","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2025.102699_bib0011","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/ecco-jcc\/jjac030","article-title":"Efficacy and safety of maintenance ustekinumab for ulcerative colitis through 3 years: UNIFI long-term extension","volume":"16","author":"Abreu","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.clinre.2025.102699_bib0012","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/apt.15706","article-title":"The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn\u2019s disease refractory to anti-tumour necrosis factor","volume":"51","author":"Alric","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinre.2025.102699_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.dld.2024.01.181","article-title":"Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: results from a real-world multicenter study","author":"Hup\u00e9","year":"2024","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.clinre.2025.102699_bib0014","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ibd\/izy322","article-title":"Treatment persistence of Infliximab versus adalimumab in ulcerative colitis: a 16-year single-center experience","volume":"25","author":"Pouillon","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.clinre.2025.102699_bib0015","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3109\/00365521.2015.1019558","article-title":"Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study","volume":"50","author":"Christensen","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.clinre.2025.102699_bib0016","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10620-016-4398-5","article-title":"Adalimumab maintenance treatment in ulcerative colitis: outcomes by prior anti-TNF use and efficacy of dose escalation","volume":"62","author":"Taxonera","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clinre.2025.102699_bib0017","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.14309\/ajg.0000000000001842","article-title":"Efficacy and safety of Infliximab retreatment in Crohn\u2019s disease: a multicentre, prospective, observational cohort (REGAIN) study from the GETAID","volume":"117","author":"Boschetti","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinre.2025.102699_bib0018","first-page":"6","article-title":"Real-world comparison of effectiveness between tofacitinib and ustekinumab in patients with ulcerative colitis exposed to at least one anti-TNF agent: results from the TORUS study","volume":"19","author":"Buisson","year":"2023","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.clinre.2025.102699_bib0019","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/apt.17570","article-title":"Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: a propensity-matched cohort study","volume":"58","author":"Kochhar","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinre.2025.102699_bib0020","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.cgh.2022.09.018","article-title":"I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease","volume":"21","author":"Peyrin-Biroulet","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2025.102699_bib0021","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.cgh.2020.02.009","article-title":"Predicting, preventing, and managing treatment-related complications in patients with inflammatory bowel diseases","volume":"18","author":"Beaugerie","year":"2020","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125001767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125001767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:59:50Z","timestamp":1761965990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740125001767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2210740125001767"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102699","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of third-line advanced therapies in patients with ulcerative colitis: A multicentre retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102699","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102699"}}